Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Boehringer Ingelheim Stories

2014-02-04 23:01:40

The Firm is evaluating Pradaxa lawsuits on behalf of clients who allegedly suffered life-threatening and uncontrollable internal hemorrhaging due to their use of the blood thinner. New York, New York (PRWEB) February 04, 2014 The federal judge overseeing thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) that allege the blood thinner caused patients to suffer life-threatening and uncontrollable internal hemorrhaging has granted a request by plaintiffs to unseal dozens of...

2014-01-30 12:28:26

Unique academic-industry partnership will include an IPF patient registry and biomarker bank RIDGEFIELD, Conn. and DURHAM, N.C., Jan. 30, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. As part of the partnership, Boehringer Ingelheim and Duke Clinical Research Institute will...

2014-01-23 12:29:16

SAN DIEGO, Jan. 23, 2014 /PRNewswire/ -- Formex, LLC ("Formex"), a leader in pharmaceutical formulation and clinical trial manufacturing, announced today its sponsorship of the 3rd Drug Formulation & Bioavailability Conference to be held in Boston, MA from January 27-29, 2014. Formex CSO Blair West, Ph.D. will be joined by distinguished speakers from Merck & Co, F Hoffman-La Roche, Novartis and Boehringer-Ingelheim for a discussion entitled "Accelerating Time to Market...

2014-01-13 04:21:01

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody(TM) research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept...

2013-12-24 23:00:41

The Firm is investigating Pradaxa lawsuits on behalf of patients who allegedly suffered life-threatening Pradaxa bleeding side effects. New York, NY (PRWEB) December 24, 2013 Thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/ ) continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to an Order issued on December 18, 2013, U.S. District Judge David R. Herndon is...

2013-12-20 16:24:22

New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an investigational basal (long-acting) insulin. LY2963016 is a new insulin glargine product developed for the treatment of...

2013-12-18 12:25:51

MENLO PARK, Calif. and INGELHEIM, Germany, Dec. 18, 2013 /PRNewswire/ -- Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. Circuit Therapeutics' key technology, optogenetics, allows...

2013-12-12 23:01:45

The Federal Judge Overseeing Hundreds of Pradaxa Lawsuits Has Fined Boehringer Ingelheim More Than $931,000 After Finding the Company Failed to Preserve Documents Sought by Plaintiffs in Pradaxa Bleeding Litigation Columbus, OH (PRWEB) December 12, 2013 The Pradaxa lawyers at Wright & Schulte LLC are disturbed by a recent court filing that indicates Boehringer Ingelheim had failed to preserve a large amount of evidence relevant to Pradaxa lawsuits now pending in a multidistrict...

2013-12-11 23:02:21

Kristine Kraft, of the Pharmaceuticals and Medical Device Litigation Department at Schlichter, Bogard & Denton, LLP representing victims of dangerous pharmaceutical medications and unsafe medical devices, comments on Judge Herndon’s order imposing sanctions on the makers of Pradaxa® for their discovery violations. Saint Louis, MO (PRWEB) December 11, 2013 On December 9, 2013, the federal court presiding over the Pradaxa® multi-district litigation currently underway in the...

2013-12-11 08:32:30

GLENDALE, Calif. and RIDGEFIELD, Conn., Dec. 11, 2013 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed") (OTCQB: AMEH), an integrated physician-driven healthcare delivery company, and Boehringer Ingelheim Pharmaceuticals, Inc., a research-based, global pharmaceutical company, today announced a partnership dedicated to managing the care of ApolloMed ACO patients with chronic obstructive pulmonary disease (COPD). Boehringer Ingelheim has a vast array of provider and patient...